The Efficacy of Epigallocatechin-3-gallate (green Tea) in the Treatment of Alzheimer's Disease: an Overview of Pre-clinical Studies and Translational Perspectives in Clinical Practice

Overview

Journal Infect Agent Cancer

Publisher Biomed Central

Specialty Infectious Diseases

Date 2017 Jun 24

PMID 28642806

Citations 63

Authors

Marco Cascella

Sabrina Bimonte

Maria Rosaria Muzio

Vincenzo Schiavone

Arturo Cuomo

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form of dementia characterized by cognitive and memory impairment. One of the mechanism involved in the pathogenesis of AD, is the oxidative stress being involved in AD's development and progression. In addition, several studies proved that chronic viral infections, mainly induced by Human herpesvirus 1 (HHV-1), Cytomegalovirus (CMV), Human herpesvirus 2 (HHV-2), and Hepatitis C virus (HCV) could be responsible for AD's neuropathology. Despite the large amount of data regarding the pathogenesis of Alzheimer's disease (AD), a very limited number of therapeutic drugs and/or pharmacological approaches, have been developed so far. It is important to underline that, in recent years, natural compounds, due their antioxidants and anti-inflammatory properties have been largely studied and identified as promising agents for the prevention and treatment of neurodegenerative diseases, including AD. The ester of epigallocatechin and gallic acid, (-)-Epigallocatechin-3-Gallate (EGCG), is the main and most significantly bioactive polyphenol found in solid green tea extract. Several studies showed that this compound has important anti-inflammatory and antiatherogenic properties as well as protective effects against neuronal damage and brain edema. To date, many studies regarding the potential effects of EGCG in AD's treatment have been reported in literature. The purpose of this review is to summarize the in vitro and in vivo pre-clinical studies on the use of EGCG in the prevention and the treatment of AD as well as to offer new insights for translational perspectives into clinical practice.

Citing Articles

Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies.

Alam M, Gulzar M, Akhtar M, Rashid S, Zulfareen , Tanuja Mol Biomed. 2024; 5(1):73.

PMID: 39725830 PMC: 11671467. DOI: 10.1186/s43556-024-00240-9.

Evaluation of Selected Plant Phenolics via Beta-Secretase-1 Inhibition, Molecular Docking, and Gene Expression Related to Alzheimer's Disease.

Ucar Akyurek T, Orhan I, Senol Deniz F, Eren G, Acar B, Sen A Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598353 PMC: 11597167. DOI: 10.3390/ph17111441.

Molecular interaction mechanisms on (-)-epigallocatechin-3-gallate improving activities of inhibited acetylcholinesterase by selected organophosphorus pesticides in vitro & vivo.

Wang L, Liu J, Gui W, Zhang R, Li X, Fang L Sci Rep. 2024; 14(1):22296.

PMID: 39333189 PMC: 11436701. DOI: 10.1038/s41598-024-72637-z.

Neurodegenerative diseases and catechins: (-)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress.

Li S, Wang Z, Liu G, Chen M Front Nutr. 2024; 11:1425839.

PMID: 39149548 PMC: 11326534. DOI: 10.3389/fnut.2024.1425839.

Secondary Bioactive Metabolites from Foods of Plant Origin as Agents against Neurodegenerative Disorders.

Gomes T, Sousa P, Campos C, Perestrelo R, Camara J Foods. 2024; 13(14).

PMID: 39063373 PMC: 11275480. DOI: 10.3390/foods13142289.

References

Bimonte S, Leongito M, Barbieri A, Del Vecchio V, Barbieri M, Albino V . Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect Agent Cancer. 2015; 10:22. PMC: 4518601. DOI: 10.1186/s13027-015-0016-y. View

Wu L, Zhang Q, Zhang X, Lv C, Li J, Yuan Y . Pharmacokinetics and blood-brain barrier penetration of (+)-catechin and (-)-epicatechin in rats by microdialysis sampling coupled to high-performance liquid chromatography with chemiluminescence detection. J Agric Food Chem. 2012; 60(37):9377-83. DOI: 10.1021/jf301787f. View

Nakagawa K, Miyazawa T . Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat. J Nutr Sci Vitaminol (Tokyo). 1998; 43(6):679-84. DOI: 10.3177/jnsv.43.679. View

Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D . Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005; 25(38):8807-14. PMC: 6725500. DOI: 10.1523/JNEUROSCI.1521-05.2005. View

Ahmed H, Salem A, Sabry G, Husein A, Kotob S . Possible therapeutic uses of Salvia triloba and Piper nigrum in Alzheimer's disease-induced rats. J Med Food. 2013; 16(5):437-46. DOI: 10.1089/jmf.2012.0165. View

Mandel S, Amit T, Weinreb O, Youdim M . Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis. 2011; 25(2):187-208. DOI: 10.3233/JAD-2011-101803. View

Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H . Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis. 1998; 19(10):1771-6. DOI: 10.1093/carcin/19.10.1771. View

Mahler A, Mandel S, Lorenz M, Ruegg U, Wanker E, Boschmann M . Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?. EPMA J. 2013; 4(1):5. PMC: 3585739. DOI: 10.1186/1878-5085-4-5. View

Zhao H, Li N, Wang Q, Cheng X, Li X, Liu T . Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. Neuroscience. 2015; 310:641-9. DOI: 10.1016/j.neuroscience.2015.10.006. View

10.

He M, Liu M, Wang S, Tang Q, Yao W, Zhao H . [Research on EGCG improving the degenerative changes of the brain in AD model mice induced with chemical drugs]. Zhong Yao Cai. 2013; 35(10):1641-4. View

11.

Lee Y, Choi D, Yun Y, Han S, Oh K, Hong J . Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. J Nutr Biochem. 2012; 24(1):298-310. DOI: 10.1016/j.jnutbio.2012.06.011. View

12.

Iadecola C . The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010; 120(3):287-96. PMC: 3001188. DOI: 10.1007/s00401-010-0718-6. View

13.

Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C . Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem. 2008; 56(13):4855-73. DOI: 10.1021/jf0735073. View

14.

Cascella M, Muzio M . Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy. J Integr Med. 2017; 15(2):77-87. DOI: 10.1016/S2095-4964(17)60313-3. View

15.

Lee H, Bae J, Lee S . Protective effect of green tea polyphenol EGCG against neuronal damage and brain edema after unilateral cerebral ischemia in gerbils. J Neurosci Res. 2004; 77(6):892-900. DOI: 10.1002/jnr.20193. View

16.

Lin C, Chen T, Chiu M, Way T, Lin J . Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation. Neurobiol Aging. 2007; 30(1):81-92. DOI: 10.1016/j.neurobiolaging.2007.05.012. View

17.

Chen X, Gawryluk J, Wagener J, Ghribi O, Geiger J . Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation. 2008; 5:12. PMC: 2330033. DOI: 10.1186/1742-2094-5-12. View

18.

Jia N, Han K, Kong J, Zhang X, Sha S, Ren G . (-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus. Mol Cell Biochem. 2013; 380(1-2):211-8. DOI: 10.1007/s11010-013-1675-x. View

19.

Ali B, Jamal Q, Shams S, Al-Wabel N, Siddiqui M, Alzohairy M . In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. CNS Neurol Disord Drug Targets. 2016; 15(5):624-8. DOI: 10.2174/1871527315666160321110607. View

20.

Chang X, Rong C, Chen Y, Yang C, Hu Q, Mo Y . (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression. Exp Cell Res. 2015; 334(1):136-45. DOI: 10.1016/j.yexcr.2015.04.004. View